APA (7th ed.) Citation

Peng, S., Lin, C., Chen, I., Shen, Y., Chang, D., Chen, T. W., . . . Lu, Y. (2023). Disparity in survival benefits of pembrolizumab between Asian and non‐Asian patients with advanced cancers: A systematic review and meta‐regression analysis. Cancer Medicine, 12(19), 20035. https://doi.org/10.1002/cam4.6563

Chicago Style (17th ed.) Citation

Peng, Shang‐Hsuan, Ching‐Hung Lin, I‐Chun Chen, Ying‐Chun Shen, Dwan‐Ying Chang, Tom Wei‐Wu Chen, Shu‐Min Huang, Fu‐Chang Hu, and Yen‐Shen Lu. "Disparity in Survival Benefits of Pembrolizumab Between Asian and Non‐Asian Patients with Advanced Cancers: A Systematic Review and Meta‐regression Analysis." Cancer Medicine 12, no. 19 (2023): 20035. https://doi.org/10.1002/cam4.6563.

MLA (9th ed.) Citation

Peng, Shang‐Hsuan, et al. "Disparity in Survival Benefits of Pembrolizumab Between Asian and Non‐Asian Patients with Advanced Cancers: A Systematic Review and Meta‐regression Analysis." Cancer Medicine, vol. 12, no. 19, 2023, p. 20035, https://doi.org/10.1002/cam4.6563.